Revenue
2017
2018
2020
2021
2022
2023
2024
2025
Traws Pharma, Inc. (TRAW)
Price—Loading quote
Net income
2017
2018
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2020
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 | $231,000 | $1.2M | $787,000 | $5.5M | $11.5M | $800,000 | $4.8M | $46.2M | $1.5M |
| Research & development | $12.1M | $12.8M | $11.4M | $11.4M | $7.3M | $16.9M | $16.9M | $19.1M | $20.1M | $25.9M | $49.4M | $50.2M | $52.8M | $22.6M |
| Operating expenses | $20.7M | $142.6M | $20.5M | $19.9M | $16.7M | $25.2M | $24.5M | $26.5M | $29.2M | $35.4M | $64.5M | $67.0M | $68.5M | $29.1M |
| Operating income | −$17.9M | −$142.4M | −$20.3M | −$19.6M | −$16.5M | −$25.0M | −$23.3M | −$25.7M | −$23.7M | −$24.0M | −$63.7M | −$62.2M | −$22.3M | −$27.6M |
| EBITDAderived | −$17.8M | −$142.4M | −$20.3M | −$19.6M | −$16.5M | −$25.0M | −$23.2M | −$25.6M | −$23.6M | −$23.8M | −$63.3M | −$61.8M | −$22.0M | −$27.3M |
| Net income | $9.2M | −$166.5M | −$18.9M | −$19.0M | −$16.2M | −$25.2M | −$20.6M | −$24.1M | −$19.7M | −$24.0M | −$63.7M | −$62.5M | −$29.9M | −$26.3M |
| Basic EPSper diluted share | $0.83 | -$35.21 | -$22.57 | -$0.91 | -$0.96 | -$2.17 | -$4.99 | -$40.15 | -$4.44 | -$10.54 | -$2.94 | -$6.12 | -$15.35 | -$14.18 |
| Diluted EPSper diluted share | $0.82 | -$35.21 | -$22.57 | -$0.91 | -$0.96 | -$2.17 | -$4.99 | -$40.15 | -$4.44 | -$10.54 | -$2.94 | -$6.12 | -$15.35 | -$14.18 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuyCommon Stock · indirect | 597.7K | $1.67 | $998.2K | 1.20M |
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries C Warrants (right to buy) · derivative · indirect | 1.79M | — | — | 1.79M |
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries B Warrants (right to buy) · derivative · indirect | 597.7K | — | — | 597.7K |
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries A Warrants (right to buy) · derivative · indirect | 597.7K | — | — | 597.7K |
| Dec 29, 2024Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries A Warrant (right to buy) · derivative · indirect | 96.3K | — | — | 96.3K |